Kenneth Sutton

789 total citations
15 papers, 87 citations indexed

About

Kenneth Sutton is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Kenneth Sutton has authored 15 papers receiving a total of 87 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 11 papers in Virology and 5 papers in Epidemiology. Recurrent topics in Kenneth Sutton's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Kenneth Sutton is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (11 papers) and HIV/AIDS Research and Interventions (5 papers). Kenneth Sutton collaborates with scholars based in United States, Belgium and Canada. Kenneth Sutton's co-authors include William Spreen, Anthony Mills, Parul Patel, Ronald D’Amico, Jeremy Roberts, Scott Letendre, Jerome De Vente, Cynthia Brinson, Debbie Hagins and Yu Lou and has published in prestigious journals such as AIDS, Journal of Antimicrobial Chemotherapy and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Kenneth Sutton

14 papers receiving 86 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth Sutton United States 5 75 64 14 11 8 15 87
Johannes Lombaard United States 2 106 1.4× 85 1.3× 20 1.4× 19 1.7× 9 1.1× 4 110
Rosemary Schluger United States 2 109 1.5× 96 1.5× 12 0.9× 14 1.3× 3 0.4× 3 125
Sara Modica Italy 5 56 0.7× 51 0.8× 11 0.8× 13 1.2× 9 1.1× 8 72
Layla Pagnucco Italy 3 73 1.0× 61 1.0× 20 1.4× 11 1.0× 5 0.6× 5 80
Dannae Brown United States 6 152 2.0× 118 1.8× 26 1.9× 32 2.9× 10 1.3× 8 158
Nokuzola Mbhele South Africa 3 54 0.7× 41 0.6× 8 0.6× 9 0.8× 16 2.0× 4 71
Arvind Kaimal Uganda 4 137 1.8× 104 1.6× 15 1.1× 32 2.9× 6 0.8× 6 152
Rafael Micán Spain 6 49 0.7× 35 0.5× 19 1.4× 33 3.0× 8 1.0× 19 79
Jordi Casabona Spain 5 37 0.5× 26 0.4× 17 1.2× 24 2.2× 3 0.4× 9 64
Linda J Harrison United States 5 85 1.1× 65 1.0× 17 1.2× 15 1.4× 2 0.3× 6 93

Countries citing papers authored by Kenneth Sutton

Since Specialization
Citations

This map shows the geographic impact of Kenneth Sutton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Sutton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Sutton more than expected).

Fields of papers citing papers by Kenneth Sutton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Sutton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Sutton. The network helps show where Kenneth Sutton may publish in the future.

Co-authorship network of co-authors of Kenneth Sutton

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Sutton. A scholar is included among the top collaborators of Kenneth Sutton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Sutton. Kenneth Sutton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
Tan, Darrell H. S., Clifford Kinder, Cornelius N. Van Dam, et al.. (2024). Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. JAIDS Journal of Acquired Immune Deficiency Syndromes. 98(4). 401–409. 4 indexed citations
4.
Karver, Tahilin Sanchez, Alessandro Berni, Antonella Castagna, et al.. (2023). Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial. AIDS Patient Care and STDs. 37(1). 53–59. 5 indexed citations
5.
Dunn, Michael, Kenneth Sutton, Denise Sutherland‐Phillips, et al.. (2023). 1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations
6.
McKellar, Mehri S., Christopher Bettacchi, Jonathan B. Angel, et al.. (2023). 1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF. Open Forum Infectious Diseases. 10(Supplement_2). 3 indexed citations
7.
Sutton, Kenneth, Jerome De Vente, Roger LeBlanc, et al.. (2022). Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study. Open Forum Infectious Diseases. 9(4). ofac067–ofac067. 2 indexed citations
8.
Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2021). Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. AIDS. 36(2). 195–203. 25 indexed citations
9.
Wu, Sterling, Feifan Zhang, David Dorey, et al.. (2020). 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. Open Forum Infectious Diseases. 7(Supplement_1). S544–S544. 2 indexed citations
10.
D’Amico, Ronald, Paul Benn, Cynthia McCoig, et al.. (2020). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S847–S848. 2 indexed citations
11.
Mills, Anthony, Gary Richmond, Cheryl Newman, et al.. (2020). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open Forum Infectious Diseases. 7(Supplement_1). S186–S187. 1 indexed citations
12.
Patel, Parul, Zhengyu Xue, Karen S. King, et al.. (2020). Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. Journal of Antimicrobial Chemotherapy. 75(8). 2240–2248. 7 indexed citations
13.
Smith, Graham, Keith Henry, Daniel Podzamczer, et al.. (2020). 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results. Open Forum Infectious Diseases. 7(Supplement_1). S379–S380. 2 indexed citations
14.
Margolis, David M., Kenneth Sutton, Jerome De Vente, et al.. (2019). 2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results. Open Forum Infectious Diseases. 6(Supplement_2). S66–S67. 8 indexed citations
15.
Letendre, Scott, Anthony Mills, Debbie Hagins, et al.. (2019). Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. Journal of Antimicrobial Chemotherapy. 75(3). 648–655. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johannes Lombaard Breakdown of academic impact, for papers by Rosemary Schluger Breakdown of academic impact, for papers by Sara Modica Breakdown of academic impact, for papers by Layla Pagnucco Breakdown of academic impact, for papers by Dannae Brown Breakdown of academic impact, for papers by Nokuzola Mbhele Breakdown of academic impact, for papers by Arvind Kaimal Breakdown of academic impact, for papers by Rafael Micán Breakdown of academic impact, for papers by Jordi Casabona Breakdown of academic impact, for papers by Linda J Harrison
Rankless by CCL
2026